Abstract:DNA polymerase theta (Pol theta), also known as DNA polymerase theta, is the member of the DNA polymerase A family and plays a crucial role in the repair of DNA double-strand breaks (DSB). Pol theta has 3 distinct structural domains: the N-terminal helicase-like domain with a conserved sequence, the C-terminal polymerase domain, and the central domain, which is a disordered sequence connecting these two regions. Notably, Pol theta is the only known polymerase in eukaryotes that possesses helicase activity. However, it is also an error-prone polymerase. When DNA DSBs occur, a specialized network consisting of at least 4 pathways, including classical-non homologous end joining (C-NHEJ), homologous recombination (HR), single-strand annealing (SSA), and alternative-end joining (Alt-EJ), is responsible for repairing DNA damage caused by DSBs. In the absence of major DNA repair pathways like HR, cells rely on Alt-EJ pathway mediated by Pol theta to repair damaged DNA and maintain genomic stability. Nevertheless, due to the low fidelity of Pol theta, Alt-EJ repair often leads to errors.Depletion of Pol theta has shown to increases DSB formation and compromise genomic stability. Conversely,overexpression of Pol theta has been associated with increases DNA damage markers and impairs cell cycle progression. As a result, the impact of Pol theta on genome stability remains controversial. Furthermore,overexpression of Pol theta is frequently observed in cancer and is associated with a characteristic mutational signature and poor prognosis. Depleting Pol theta in an HR-deficient background has been shown to impair cell viability, suggesting a synthetic lethal (SL) relationship between Pol theta and HR factors. In recent years, targeted chemotherapy drugs that inhibit tumor growth have gained significant attention. However, off-target effects and drug resistance pose challenges for clinical application, particularly with poly-ADP-ribose polymerase inhibitor (PARPi). Blocking Pol theta activity in HR-deficient tumor cells has been found to reverse PARPi resistance, making Pol theta a very promising therapeutic target in cancer treatment. The availability of crystal structures for both helicase and polymerase domain has facilitated the design of potent inhibitors of Pol theta. Currently, several highly specific and effective small molecule inhibitors targeting Pol theta, such as Novobiocin, RP-6685, and ART558, have been reported to effectively block various cancers with HR deficiency. The initial success of these inhibitors points to new directions for treating BRCA1/2-mutated tumors. Additionally, reducing the Alt-EJ repair pathway mediated by Pol theta can improve HR repair efficiency and increase the chance of exogenous gene target integration (TI),suggesting potential new applications for Pol theta inhibitors. This article reviews the recent research progress on the molecular function of Pol theta and its involvement in the Alt-EJ pathway modification mechanism, providing insights for a deeper understanding of this field.

REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps

BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage

MRNIP limits ssDNA gaps during replication stress

USP1-dependent nucleolytic expansion of PRIMPOL-generated nascent DNA strand discontinuities during replication stress

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

EXO1-mediated ssDNA gap expansion is essential for ATR activation and to maintain viability in BRCA1-deficient cells

ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination

EXO1 and DNA2-mediated ssDNA gap expansion is essential for ATR activation and to maintain viability in BRCA1-deficient cells

<i>ZNF251</i>haploinsufficiency confers PARP inhibitors resistance in<i>BRCA1</i>-mutated cancer cells through modulation of RAD51 and DNA-PKcs-dependent pathways

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps

CRISPR knockout genome-wide screens identify the HELQ-RAD52 axis in regulating the repair of cisplatin-induced single stranded DNA gaps

RAD52 prevents accumulation of Polalpha-dependent replication gaps at perturbed replication forks in human cells

C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

Tolerating DNA damage by repriming: Gap filling in the spotlight

Abstract IA014: BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells.

"Bridging the DNA divide": Understanding the interplay between replication- gaps and homologous recombination proteins RAD51 and BRCA1/2

DNA Polymerase Θ: a Multifunctional and Error-prone DNA End Repair Enzyme

53bp1 Inhibits Homologous Recombination In Brca1-Deficient Cells By Blocking Resection Of Dna Breaks